News

Richmond pharma company Kaléo Acquired

New York-based Marathon Asset Management LP announced it has entered into a definitive agreement to acquire Richmond-based privately held pharmaceutical company Kaléo Inc., which is known for treating allergic anaphylaxis and opioids overdoses.

The total base purchase price is approximately $310 million in cash, less certain adjustments and includes potential net revenue-based milestone payments of up to approximately $70 million in cash for the 2022 and 2023 fiscal years, in a transaction that will provide liquidity for Kaléo shareholders upon closing, according to a news release from Marathon.

“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” Dr. Evan Bedil, Marathon’s head of healthcare, said in a statement. “We plan to leverage the company’s strong portfolio of intellectual property, its leading reputation among allergists and its experienced management team to pursue multiple avenues of growth in the coming years.”

The company’s headquarters will remain in Richmond.

Additionally, Richmond-based plastic films and aluminum extrusions manufacturer Tredegar Corp. is selling its 18% ownership stake in Kaléo, which is about 3.3 million shares, the company announced Monday. Tredegar is a 1989 spinoff of Ethyl Crop., which now operates as NewMarket Corp.

Twin brothers Dr. Eric Edwards and Evan Edwards founded Kaléo in 2005 and left in 2019. Eric Edwards co-founded Phlow Corp., another Richmond-based company developing new ways to manufacture essential medicines.

Phlow has plans to open a $125 million plant in Petersburg. In May 2020, Phlow was awarded a $354 million, four-year federal contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce the essential medications using advanced manufacturing processes from the Medicines for All Institute based at Virginia Commonwealth University’s College of Engineering.

Kaléo, which has more than 200 issued patents, developed the patented Aerio Auto-Injection Platform for treating allergic anaphylaxis and opioids overdoses. It also developed Evzio, a prescription medicine used to treat opioid emergencies, such as overdoses. The company commercialized the AUVI-Q epinephrine injector, which distributes 0.15 mg and 0.3 mg doses, and the AUVI-q, which injects 0.1 mg of epinephrine and is designed for infants and toddlers.

In 2020, Kaléo started offering its auto-injector under the name Allerject in Canada.

“Kaléo’s executive management team enthusiastically looks forward to joining forces with Marathon, which has been a strong ally of Kaléo as a lender for many years,” Kaléo President and CEO Ronald Gunn said in a statement. “With its vast resources and well-established capital base, we have found the strongest possible partner to help us commercialize our significant intellectual property and write the next chapter in Kaléo’s story.”

The Kaléo Board of Directors and shareholders have unanimously approved the transaction, which is expected to close on or before Dec. 31.

 

Read more here.

Recent News

11/30/2023

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding

11/30/2023

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research

11/27/2023

cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged